BioCentury | Sep 18, 2017
Company News

Management tracks: Kamada, Vertex, Addex, Achillion

...the company. Formerly CEO of MirImmune Inc. , Eliseev joined RXi in January when it acquired MirImmune...
BioCentury | Oct 17, 2016
Company News

MirImmune, RXi Pharmaceuticals deal

...RXi received an exclusive option to acquire immunotherapy company MirImmune. If exercised, MirImmune would receive a...
...Aug. 5. RXi may exercise the option before April 5, 2017. Last year, RXi granted MirImmune...
...technologies sd-rxRNA and rxRNAori to develop cell-based cancer immunotherapies involving ex vivo modification of cells. MirImmune...
BioCentury | May 4, 2015
Company News

RXi Pharmaceuticals, MirImmune deal

...RXi granted MirImmune an exclusive license to use RNAi delivering technology, sd-rxRNA and rxRNAori, to develop...
...to develop cell-based cancer immunotherapies. MirImmune is responsible for R&D, manufacturing, regulatory approval and commercialization. MirImmune...
...income and single-digit royalties. RXi has an option to acquire a double-digit equity stake in MirImmune...
Items per page:
1 - 3 of 3
BioCentury | Sep 18, 2017
Company News

Management tracks: Kamada, Vertex, Addex, Achillion

...the company. Formerly CEO of MirImmune Inc. , Eliseev joined RXi in January when it acquired MirImmune...
BioCentury | Oct 17, 2016
Company News

MirImmune, RXi Pharmaceuticals deal

...RXi received an exclusive option to acquire immunotherapy company MirImmune. If exercised, MirImmune would receive a...
...Aug. 5. RXi may exercise the option before April 5, 2017. Last year, RXi granted MirImmune...
...technologies sd-rxRNA and rxRNAori to develop cell-based cancer immunotherapies involving ex vivo modification of cells. MirImmune...
BioCentury | May 4, 2015
Company News

RXi Pharmaceuticals, MirImmune deal

...RXi granted MirImmune an exclusive license to use RNAi delivering technology, sd-rxRNA and rxRNAori, to develop...
...to develop cell-based cancer immunotherapies. MirImmune is responsible for R&D, manufacturing, regulatory approval and commercialization. MirImmune...
...income and single-digit royalties. RXi has an option to acquire a double-digit equity stake in MirImmune...
Items per page:
1 - 3 of 3